Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C28H44O |
Molecular Weight | 396.6484 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 3 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C3\C[C@@H](O)CCC3=C)[C@H](C)\C=C\[C@H](C)C(C)C
InChI
InChIKey=MECHNRXZTMCUDQ-RKHKHRCZSA-N
InChI=1S/C28H44O/c1-19(2)20(3)9-10-22(5)26-15-16-27-23(8-7-17-28(26,27)6)12-13-24-18-25(29)14-11-21(24)4/h9-10,12-13,19-20,22,25-27,29H,4,7-8,11,14-18H2,1-3,5-6H3/b10-9+,23-12+,24-13-/t20-,22+,25-,26+,27-,28+/m0/s1
Molecular Formula | C28H44O |
Molecular Weight | 396.6484 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 3 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.drugbank.ca/drugs/DB00153Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/dosage/ergocalciferol.html
Sources: http://www.drugbank.ca/drugs/DB00153
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/dosage/ergocalciferol.html
Ergoalcifediol (Vitamin D2) is a fat soluble steroid hormone precursor of vitamin D. The principal biologic function of vitamin D is the maintenance of normal levels of serum calcium and phosphorus in the bloodstream by enhancing the efficacy of the small intestine to absorb these minerals from the diet. Cholecalciferol is synthesized within our bodies naturally, but if UV exposure is inadequate or the metabolism of cholecalciferol is abnormal, then an exogenous source is required. Vitamin D2 is converted to 25-hydroxyvitamin D (25OHD) in the liver, and then to the active form, 1,25-dihydroxyvitamin D (1,25(OH)2D), in the kidney. Once transformed, it binds to the vitamin D receptor, which leads to a variety of regulatory roles. Vitamin D plays an important role in maintaining calcium balance and in the regulation of parathyroid hormone (PTH). It promotes renal reabsorption of calcium, increases intestinal absorption of calcium and phosphorus, and increases calcium and phosphorus mobilization from bone to plasma. Very few foods naturally contain vitamin D. Sources that contain the vitamin include fatty fish, the liver and fat of aquatic mammals (e.g., seals, polar bears), and eggs from chickens fed vitamin D-fortified feed. As such, many countries have instituted policies to fortify certain foods with vitamin D to compensate for the potentially low exposures of skin to sunlight. Vitamin D deficiency results in inadequate mineralization of bone or compensatory skeletal demineralization and causes decreased ionized calcium concentrations in blood and a resultant increase in the production and secretion of PTH. Increase in PTH stimulates the mobilization of skeletal calcium, inhibits renal excretion of calcium, and stimulates renal excretion of phosphorus. This results in normal fasting serum calcium concentrations and low or near-normal serum phosphorus. The enhanced mobilization of skeletal calcium induced by this secondary hyperparathyroidism leads porotic bone. Ergoalcifediol is used for use in the management of hypocalcemia and its clinical manifestations in patients with hypoparathyroidism, as well as for the treatment of familial hypophosphatemia (vitamin D resistant rickets). This drug has also been used in the treatment of nutritional rickets or osteomalacia, vitamin D dependent rickets, rickets or osteomalacia secondary to long-term high dose anticonvulsant therapy, early renal osteodystrophy, osteoporosis (in conjunction with calcium), and hypophosphatemia associated with Fanconi syndrome (with treatment of acidosis). Ergocalciferol is manufactured and marketed under various names, including Deltalin (Eli Lilly and Company), Drisdol (Sanofi-Synthelabo) and Calcidol (Patrin Pharma).
CNS Activity
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24466410
Curator's Comment: Discovered in 1932
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1977 Sources: http://www.drugbank.ca/drugs/DB00153 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Ergocalciferol Approved UseErgocalciferol is indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin D resistant rickets, and familial hypophosphatemia. Launch Date2009 |
|||
Primary | Ergocalciferol Approved UseErgocalciferol is indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin D resistant rickets, and familial hypophosphatemia. Launch Date2009 |
|||
Primary | Ergocalciferol Approved UseErgocalciferol is indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin D resistant rickets, and familial hypophosphatemia. Launch Date2009 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
46.92 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25782422/ |
125 μg 1 times / day multiple, oral dose: 125 μg route of administration: Oral experiment type: MULTIPLE co-administered: |
CALCIFEDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2324.1 ng × day/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25782422/ |
125 μg 1 times / day multiple, oral dose: 125 μg route of administration: Oral experiment type: MULTIPLE co-administered: |
CALCIFEDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
33 day EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25782422/ |
125 μg 1 times / day multiple, oral dose: 125 μg route of administration: Oral experiment type: MULTIPLE co-administered: |
CALCIFEDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
15 mg multiple, oral (total) Highest studied dose |
unknown, 7 months n = 1 Health Status: unknown Age Group: 7 months Sex: M Population Size: 1 Sources: |
Other AEs: Renal failure... |
0.5 mg 1 times / week multiple, oral Highest studied dose Dose: 0.5 mg, 1 times / week Route: oral Route: multiple Dose: 0.5 mg, 1 times / week Sources: |
unknown, 80.1 ± 10.0 years n = 70 Health Status: unknown Age Group: 80.1 ± 10.0 years Sex: M+F Population Size: 70 Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Renal failure | 1 patient | 15 mg multiple, oral (total) Highest studied dose |
unknown, 7 months n = 1 Health Status: unknown Age Group: 7 months Sex: M Population Size: 1 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
The effect of cortisone on vitamin D2-induced nephrocalcinosis in the rat. | 1957 Feb |
|
Degranulation of the parafollicular cells of the rat thyroid by vitamin-D2-induced hypercalcemia. | 1968 Jul |
|
Chlorothiazide-induced hypercalcemia in juvenile osteoporosis and hyperparathyroidism. | 1969 Jul 10 |
|
A comparison of the toxicity of ergocalciferol and cholecalciferol in rhesus monkeys (Macaca mulatta). | 1972 Aug |
|
Myopathy associated with anticonvulsant osteomalacia. | 1973 Dec 1 |
|
Determination of vitamin D and its metabolites in plasma from normal and anephric man. | 1979 Jul 15 |
|
Does somatostatin in each organ act specifically on that particular organ? | 1979 Sep |
|
Inhibition of vitamin D2-induced arteriosclerosis in rats by depletion of complement with cobra venom factor. | 1980 |
|
Prevention of osteonecrosis following renal transplantation by using vitamin D2 (ergocalciferol). | 1983 |
|
Reversal of vitamin-D2-induced hypercalciuria by chlorothiazide. | 1983 Feb |
|
Vitamin D2-induced arteriosclerosis in spontaneously hypertensive rats and protection by diltiazem, a calcium antagonist. | 1984 Jun |
|
Vitamin D2-induced hypercalcemia in rat lens. | 1986 Mar |
|
X-linked hypophosphatemia: normal renal function despite medullary nephrocalcinosis 25 years after transient vitamin D2-induced renal azotemia. | 1997 Dec |
|
Steroids as possible inhibitors of HIV-1 protease. | 1998 Apr 16 |
|
Current understanding of the molecular actions of vitamin D. | 1998 Oct |
|
Comparative effects of vitamin K2 and vitamin E on experimental arteriosclerosis. | 1999 Jan |
|
Perinatal metabolism of vitamin D. | 2000 May |
|
In situ detection of 1,25-dihydroxyvitamin D3 receptor in human skeletal muscle tissue. | 2001 Jan |
|
Vitamin D receptor as an intestinal bile acid sensor. | 2002 May 17 |
|
A novel mutation in helix 12 of the vitamin D receptor impairs coactivator interaction and causes hereditary 1,25-dihydroxyvitamin D-resistant rickets without alopecia. | 2002 Nov |
|
[Disturbances of calcium-PTH-vitamin D axis in chronic liver diseases]. | 2004 Aug |
|
Overview of general physiologic features and functions of vitamin D. | 2004 Dec |
|
Vitamin D receptor expression in human muscle tissue decreases with age. | 2004 Feb |
|
Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. | 2004 Jan 1 |
|
The prostate 25-hydroxyvitamin D-1 alpha-hydroxylase is not influenced by parathyroid hormone and calcium: implications for prostate cancer chemoprevention by vitamin D. | 2004 Jun |
|
The role of vitamin D in the prevention of osteoporosis. | 2005 |
|
Spotlight on paricalcitol in secondary hyperparathyroidism. | 2005 |
|
The high prevalence of inadequate serum vitamin D levels and implications for bone health. | 2005 Apr |
|
Serum parathyroid hormone (PTH) levels in smokers and non-smokers. The fifth Tromsø study. | 2005 Jan |
|
Failure of high-dose ergocalciferol to correct vitamin D deficiency in adults with cystic fibrosis. | 2005 Jul 15 |
|
Prevalence and correction of 25(OH) vitamin D deficiency in peritoneal dialysis patients. | 2005 Jul-Aug |
|
Estimates of beneficial and harmful sun exposure times during the year for major Australian population centres. | 2006 Apr 3 |
|
Vitamin D and calcium receptors: links to hypercalciuria. | 2006 Jul |
|
Renal osteodystrophy in children: a systemic disease associated with cardiovascular manifestations. | 2006 Jul |
|
Severe hypercalcemia after transition from calcium carbonate to calcium citrate in an elderly woman treated with ergocalciferol 50,000 IU per day. | 2006 Mar |
|
Protective effect of lysozyme chloride on gastric oxidative stress and hemorrhagic ulcers in severe atherosclerotic rats. | 2007 Dec |
|
Protective effect of verapamil on gastric hemorrhagic ulcers in severe atherosclerotic rats. | 2007 Dec 31 |
|
Comprehensive analysis of the effects of ordinary nutrients on hepatitis C virus RNA replication in cell culture. | 2007 Jun |
|
A cardiac-specific robotized cellular assay identified families of human ligands as inducers of PGC-1α expression and mitochondrial biogenesis. | 2012 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/ergocalciferol.html
Usual Adult Dose for Hypoparathyroidism
50,000 to 200,000 international units orally daily, concomitantly with calcium lactate 4 g, six times per day
Usual Adult Dose for Rickets
12,000 to 500,000 international units orally daily
Usual Adult Dose for Familial Hypophosphatemia
12,000 to 500,000 international units orally daily
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20650254
Ergoalcifediol (1.2 nm) stimulated synthesis and intercellular deposition of rat elastic fibres and had a stabilizing effect on the musculo-elastic multilayer formed by the cultured cells.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:14:31 GMT 2023
by
admin
on
Fri Dec 15 15:14:31 GMT 2023
|
Record UNII |
VS041H42XC
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C941
Created by
admin on Fri Dec 15 15:14:31 GMT 2023 , Edited by admin on Fri Dec 15 15:14:31 GMT 2023
|
||
|
DSLD |
2476 (Number of products:490)
Created by
admin on Fri Dec 15 15:14:31 GMT 2023 , Edited by admin on Fri Dec 15 15:14:31 GMT 2023
|
||
|
NDF-RT |
N0000006337
Created by
admin on Fri Dec 15 15:14:31 GMT 2023 , Edited by admin on Fri Dec 15 15:14:31 GMT 2023
|
||
|
LIVERTOX |
361
Created by
admin on Fri Dec 15 15:14:31 GMT 2023 , Edited by admin on Fri Dec 15 15:14:31 GMT 2023
|
||
|
NDF-RT |
N0000175909
Created by
admin on Fri Dec 15 15:14:31 GMT 2023 , Edited by admin on Fri Dec 15 15:14:31 GMT 2023
|
||
|
NDF-RT |
N0000006337
Created by
admin on Fri Dec 15 15:14:31 GMT 2023 , Edited by admin on Fri Dec 15 15:14:31 GMT 2023
|
||
|
CFR |
21 CFR 172.379
Created by
admin on Fri Dec 15 15:14:31 GMT 2023 , Edited by admin on Fri Dec 15 15:14:31 GMT 2023
|
||
|
NDF-RT |
N0000006337
Created by
admin on Fri Dec 15 15:14:31 GMT 2023 , Edited by admin on Fri Dec 15 15:14:31 GMT 2023
|
||
|
EPA PESTICIDE CODE |
202900
Created by
admin on Fri Dec 15 15:14:31 GMT 2023 , Edited by admin on Fri Dec 15 15:14:31 GMT 2023
|
||
|
WHO-VATC |
QA11CC01
Created by
admin on Fri Dec 15 15:14:31 GMT 2023 , Edited by admin on Fri Dec 15 15:14:31 GMT 2023
|
||
|
DSLD |
206 (Number of products:56)
Created by
admin on Fri Dec 15 15:14:31 GMT 2023 , Edited by admin on Fri Dec 15 15:14:31 GMT 2023
|
||
|
NDF-RT |
N0000006337
Created by
admin on Fri Dec 15 15:14:31 GMT 2023 , Edited by admin on Fri Dec 15 15:14:31 GMT 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
27
Created by
admin on Fri Dec 15 15:14:31 GMT 2023 , Edited by admin on Fri Dec 15 15:14:31 GMT 2023
|
||
|
WHO-ATC |
A11CC01
Created by
admin on Fri Dec 15 15:14:31 GMT 2023 , Edited by admin on Fri Dec 15 15:14:31 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000090229
Created by
admin on Fri Dec 15 15:14:31 GMT 2023 , Edited by admin on Fri Dec 15 15:14:31 GMT 2023
|
PRIMARY | |||
|
m11485
Created by
admin on Fri Dec 15 15:14:31 GMT 2023 , Edited by admin on Fri Dec 15 15:14:31 GMT 2023
|
PRIMARY | Merck Index | ||
|
C29029
Created by
admin on Fri Dec 15 15:14:31 GMT 2023 , Edited by admin on Fri Dec 15 15:14:31 GMT 2023
|
PRIMARY | |||
|
819
Created by
admin on Fri Dec 15 15:14:31 GMT 2023 , Edited by admin on Fri Dec 15 15:14:31 GMT 2023
|
PRIMARY | |||
|
5280793
Created by
admin on Fri Dec 15 15:14:31 GMT 2023 , Edited by admin on Fri Dec 15 15:14:31 GMT 2023
|
PRIMARY | |||
|
ERGOCALCIFEROL
Created by
admin on Fri Dec 15 15:14:31 GMT 2023 , Edited by admin on Fri Dec 15 15:14:31 GMT 2023
|
PRIMARY | Other name: Vitamin D2.Description: Colourless or slightly yellowish crystals or a white or slightly yellowish, crystalline powder; odourless or almost odourless.Solubility: Practically insoluble in water; freely soluble in ethanol (~750 g/l) TS, acetone R and ether R.Category: Vitamin, antirachitic.Storage: Ergocalciferol should be kept in a hermetically closed container, preferably in an inert atmosphere, such as nitrogen,protected from light and stored at a temperature between 2 and 8 ?C.Additional information: Ergocalciferol is affected by air and by light. Even in the absence of light, it is gradually degraded onexposure to a humid atmosphere, the decomposition being faster at higher temperatures.Definition: Ergocalciferol contains not less than 95.0% and not more than 105.0% of C28H44O. | ||
|
ERGOCALCIFEROL
Created by
admin on Fri Dec 15 15:14:31 GMT 2023 , Edited by admin on Fri Dec 15 15:14:31 GMT 2023
|
PRIMARY | |||
|
DTXSID5020233
Created by
admin on Fri Dec 15 15:14:31 GMT 2023 , Edited by admin on Fri Dec 15 15:14:31 GMT 2023
|
PRIMARY | |||
|
200-014-9
Created by
admin on Fri Dec 15 15:14:31 GMT 2023 , Edited by admin on Fri Dec 15 15:14:31 GMT 2023
|
PRIMARY | |||
|
SUB06596MIG
Created by
admin on Fri Dec 15 15:14:31 GMT 2023 , Edited by admin on Fri Dec 15 15:14:31 GMT 2023
|
PRIMARY | |||
|
28934
Created by
admin on Fri Dec 15 15:14:31 GMT 2023 , Edited by admin on Fri Dec 15 15:14:31 GMT 2023
|
PRIMARY | |||
|
ergocalciferol
Created by
admin on Fri Dec 15 15:14:31 GMT 2023 , Edited by admin on Fri Dec 15 15:14:31 GMT 2023
|
PRIMARY | |||
|
DB00153
Created by
admin on Fri Dec 15 15:14:31 GMT 2023 , Edited by admin on Fri Dec 15 15:14:31 GMT 2023
|
PRIMARY | |||
|
2838
Created by
admin on Fri Dec 15 15:14:31 GMT 2023 , Edited by admin on Fri Dec 15 15:14:31 GMT 2023
|
PRIMARY | |||
|
CHEMBL1536
Created by
admin on Fri Dec 15 15:14:31 GMT 2023 , Edited by admin on Fri Dec 15 15:14:31 GMT 2023
|
PRIMARY | |||
|
62792
Created by
admin on Fri Dec 15 15:14:31 GMT 2023 , Edited by admin on Fri Dec 15 15:14:31 GMT 2023
|
PRIMARY | |||
|
382
Created by
admin on Fri Dec 15 15:14:31 GMT 2023 , Edited by admin on Fri Dec 15 15:14:31 GMT 2023
|
PRIMARY | |||
|
VS041H42XC
Created by
admin on Fri Dec 15 15:14:31 GMT 2023 , Edited by admin on Fri Dec 15 15:14:31 GMT 2023
|
PRIMARY | |||
|
4018
Created by
admin on Fri Dec 15 15:14:31 GMT 2023 , Edited by admin on Fri Dec 15 15:14:31 GMT 2023
|
PRIMARY | RxNorm | ||
|
50-14-6
Created by
admin on Fri Dec 15 15:14:31 GMT 2023 , Edited by admin on Fri Dec 15 15:14:31 GMT 2023
|
PRIMARY | |||
|
1239005
Created by
admin on Fri Dec 15 15:14:31 GMT 2023 , Edited by admin on Fri Dec 15 15:14:31 GMT 2023
|
PRIMARY | |||
|
VS041H42XC
Created by
admin on Fri Dec 15 15:14:31 GMT 2023 , Edited by admin on Fri Dec 15 15:14:31 GMT 2023
|
PRIMARY | |||
|
SUB127287
Created by
admin on Fri Dec 15 15:14:31 GMT 2023 , Edited by admin on Fri Dec 15 15:14:31 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |